Home / Organizations / Valeant Pharmaceuticals

Valeant Pharmaceuticals

Valeant Pharmaceuticals is a publicly traded pharmaceutical company based in Montreal, Canada. The company has a diverse product portfolio with focus on branded pharmaceuticals, branded generics and over-the-counter products. It has specialization in dermatology, eye health, neurology and consumer healthcare. In addition, Valeant Pharmaceuticals has a portfolio of more than 500 products from its prior history as a group of specialty chemical and radiochemical research, development and supply companies.

One of the growth strategy for Valeant has been acquisitions, sometimes in the multi-billion dollar range, of medical and pharmaceutical companies. This year itself Valeant Pharmaceuticals completeed its acquisition of substantially all the assets of Dendreon Corporation, including worldwide rights to PROVENGE, an immunotherapy treatment for advanced prostate cancer. As of July 2015, the company was valued at over $116 billion by market capitalization, making it the largest public company in Canada and the largest pharmaceutical company in the nation.

Product Portfolio:

  • Cesamet (nabilone)
  • Efudex
  • Mestinon
  • Diastat
  • Ribavirin (licensed to Schering Plough)

Company Information

Type Public company
Traded as NYSE: VRX
TSX: VRX
S&P/TSX 60 component
Industry Pharmaceutical industry
Founded 1960
Founder August and Marie Krogh
Headquarters Laval, Quebec, Canada
Key people J. Michael Pearson (Chairman & CEO)
Howard B. Schiller (CFO)
Products Cesamet (nabilone), Efudex, Mestinon, Diastat, Ribavirin (licensed to Schering Plough), CeraVe
Revenue US$2.73 billion (Q2 2015
Net income
Number of employees NA
Subsidiaries Bausch & Lomb, Salix Pharmaceuticals, Medicis Pharmaceutical, Solta Medical, Dendreon, OraPharma, Obagi
Website www.valeant.com

Check Also

Teva Pharmaceutical Industries Ltd.

The company known today as Teva Pharmaceutical Industries Ltd. was established in Jerusalem in 1901. It …